About

Tom joined F-Prime Capital as an Executive Partner in September, 2007. Most recently, he served as President, Chief Operating Officer at Dyax Corp. Prior to that, he held positions at UCB Pharma (Corporate Vice President, Director of Global Research and Development), CytoMed, Inc (Chairman and Chief Executive Officer), and Enzytech, Inc (President). He began his industry career at Smith Kline and French, where he held positions in both clinical development and business development. Dr. Beck is Board-certified in Internal Medicine and Nephrology and was Assistant Professor of Medicine at Temple University School of Medicine prior to joining the pharmaceutical industry. He received his B.S. degree from Yale University and his M.D. from Cornell University. Since joining F-Prime Capital, Dr. Beck has been on the boards of NeuroTherapeutics Pharma, Topaz Pharmaceuticals, Vicept Therapeutics, Mersana Therapeutics, Symbiomix, and Dimension Therapeutics. He is currently on the board of Adagene, Ltd, Nocion Therapeutics, Akrevia, and Promentis Therapeutics where he is currently serving as Chief Medical Officer. He has been CEO of Topaz Pharmaceuticals and Dimension Therapeutics.

  • Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunodermatology. Learn more at www.aclaristx.com.

  • Adagene is an antibody discovery and engineering company with proprietary Smart Antibody Technology, which increases success rates, substantially accelerates time to market, and reduces the costs associated with developing a therapeutic antibody. Learn more at www.adagene.com.

  • Akrevia Therapeutics is focused on developing highly-potent, targeted and combinable immuno-oncology therapeutics by delivering natural and engineered biologics in the tumor microenvironment. Learn more at www.akrevia.com.

  • Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions
    to patients suffering from CNS disorders. Arvelle is responsible for the development and
    commercialization of cenobamate, an investigational antiepileptic drug, in the European market.  Learn more at www.arvelletx.com.

    • Category

      • Therapeutics
    • Status

      • Private
    • Location

      Basel, Switzerland

    • Year Invested

      2019

    • Team

  • CardioKine is a pharmaceutical company focused on the development of lixivaptan, an oral compound under development for the potential treatment of hyponatremia in patients with congestive heart failure. CardioKine was acquired by Cornerstone Therapeutics.

  • Dimension Therapeutics was a leader in the development of AAV (adeno-associated virus) gene therapies for rare disease. Dimension Therapeutics was acquired by Ultragenyx Pharmaceuticals (NASDAQ:RARE).

  • Mersana Therapeutics (NASDAQ:MRSN) has its lead product candidate, XMT-1536, in clinical trials in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines. Learn more at www.mersana.com.

    • Category

      • Therapeutics
    • Status

      • Public
    • Location

      Cambridge, MA

    • Year Invested

      2005

    • Team

  • Nocion Therapeutics, a neuroinflammation and analgesic company discovering and developing novel pharmaceutical treatments for various indications including pain, cough and itch.  Learn more at www.nociontx.com.

    • Category

      • Therapeutics
    • Status

      • Private
    • Location

      Cambridge, MA

    • Year Invested

      2019

    • Team

  • Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company, is developing innovative therapies for neuropsychiatric disorders. Learn more at www.promentispharma.com.

    • Category

      • Therapeutics
    • Status

      • Private
    • Location

      Milwaukee, Wisconsin

    • Year Invested

      2016

    • Team

  • Symbiomix developed the first oral, single dose treatment in the United States for bacterial vaginosis (BV), a common gynecological infection that increases the risk of serious health problems. Symbiomix was acquired by Lupin Pharmaceuticals. Learn more at www.symbiomix.com.

  • Topaz Pharmaceuticals is a specialty pharmaceutical company developing a topical prescription product, Sklice, for the treatment of head lice. Topaz Pharmaceuticals was acquired by Sanofi.

     

  • Vicept Therapeutics is a dermatology specialty pharmaceutical company developing a topical prescription product for the treatment of the chronic skin condition, Rosacea. Vicept Therapeutics was acquired by Allergan.